Key Metrics of Enlivex Ltd.
Revenue—FY 2023
Operating income−$29.4M▼ 13.9% YoY
Net profit−$29.1M▲ 6.4% YoY
Shareholders' equity$30.1M
Market cap$4.0MENLV · $0.20
Competitors10identified
About Enlivex Ltd.
Sectors
Company details
- Founded
- 2014
- Listed
- Nasdaq: ENLV (since 2014)
Operational Areas of Enlivex Ltd.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameEnlivex Ltd.
TickerENLV
ExchangeNasdaq
CountryIsrael
SEC CIK0001596812
Listed since2014
IndustryBiotechnology: Pharmaceutical Preparations
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
ENLV · Nasdaq · SEC CIK 0001596812
Last price · 25 Oct 2026
$0.20
−1.48%
Market cap$4.0M
P/E—On FY 2023 diluted EPS
Volume525,117
SectorHealth CareBiotechnology: Pharmaceutical Preparations
Country · IPOIsraelListed 2014
ENLV share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Enlivex Ltd.
Competitors10identified
Countries2most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | gsk.com | 2022 | United Kingdom | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States |
Similar companies
A
Anthem Biosciences (India)Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
I
International Biotech Park LimitedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
B
Bharat Immunologicals And Biologicals Corporation LimitedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
H
Hester Biosciences LimitedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
M
Medicamen Biotech LimitedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
K
Kbk Biotech Private LimitedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
R
Royalty Pharma plcPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
A
argenx SEPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.